David Joel Cohen

Q: What Schools Are Affiliated With David Joel Cohen

David Joel Cohen is affiliated with the following schools: University of Alabama at Birmingham, University of Calgary, Université de Montréal, Tilburg University, Stony Brook University, University of Cape Town, University of Michigan, University of Missouri, University of Toledo, Columbia University, New York University, Duke University, McGill University, Yale University, Ohio State University, University of Missouri–Kansas City, University of British Columbia, University of Colorado

David Joel Cohen's AcademicInfluence.com Rankings

David Joel Cohen

Medical

#1180

World Rank

#1494

Historical Rank

Cardiology

#77

World Rank

#78

Historical Rank

Public Health

#150

World Rank

#157

Historical Rank

Epidemiology

#163

World Rank

#175

Historical Rank

medical Degrees

David Joel Cohen

Philosophy

#3994

World Rank

#6350

Historical Rank

Logic

#1556

World Rank

#2338

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

David Joel Cohen's Degrees

Bachelors Biology Stanford University
Doctorate Medicine Harvard University
PhD Epidemiology Columbia University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is David Joel Cohen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Joel Cohen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions (2007) (5088)
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. (2015) (3951)
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. (2016) (3614)
Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients (2019) (2461)
Stenting versus endarterectomy for treatment of carotid-artery stenosis. (2010) (2093)
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2012) (1784)
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2012) (1700)
Strategies for multivessel revascularization in patients with diabetes. (2012) (1569)
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. (2014) (1564)
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2012) (1192)
Transcatheter Mitral‐Valve Repair in Patients with Heart Failure (2018) (1192)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. (2003) (1177)
Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials (2001) (909)
Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis (2016) (877)
Incidence (1931) (868)
Stenting and medical therapy for atherosclerotic renal-artery stenosis. (2014) (764)
Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry (2006) (750)
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. (2001) (666)
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). (2012) (642)
Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison. (1999) (578)
Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction: Implications When Selecting a Reperfusion Strategy (2006) (574)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI. (2019) (539)
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study (2013) (532)
Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. (1994) (513)
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. (2002) (432)
Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative (2004) (427)
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. (2004) (418)
Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. (2006) (411)
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. (2016) (406)
Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease (2015) (396)
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2012) (388)
Trial of everolimus-eluting stents or bypass surgery for coronary disease. (2015) (379)
Stent Thrombosis After Successful Sirolimus-Eluting Stent Implantation (2004) (379)
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. (2007) (361)
Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. (2020) (356)
Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA. (2015) (327)
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. (2007) (304)
Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes From the Claudication Exercise Versus Endoluminal Revascularization (CLEVER) Study (2012) (303)
Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. (2010) (303)
Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials (2004) (303)
Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis (2011) (295)
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. (2006) (287)
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. (2005) (282)
Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). (2012) (276)
The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. (2006) (274)
Long-Term Clinical Outcomes After Unprotected Left Main Trunk Percutaneous Revascularization in 279 Patients (2001) (265)
Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial (2004) (265)
STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. (2020) (264)
Staging classification of aortic stenosis based on the extent of cardiac damage (2017) (246)
Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment. (1993) (240)
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. (2015) (240)
Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. (2013) (239)
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. (2021) (236)
Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data (2019) (231)
Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). (2012) (231)
Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke (2015) (231)
Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. (2011) (228)
Interpreting the results of cost-effectiveness studies. (2008) (224)
Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. (2020) (222)
Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data (2018) (217)
Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). (2017) (210)
Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. (2016) (208)
Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial). (2015) (207)
Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement: Results From the PARTNER (Placement of Aortic Transcatheter Valve) Trial (2014) (205)
Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. (2015) (199)
Age and Outcomes After Carotid Stenting and Endarterectomy: The Carotid Revascularization Endarterectomy Versus Stenting Trial (2011) (197)
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. (2008) (196)
Predictors of long-term outcome after percutaneous balloon mitral valvuloplasty. (1992) (195)
Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. (2014) (191)
Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. (2021) (189)
Vascular closure devices: the second decade. (2007) (189)
Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial (2019) (186)
Myocardial Infarction After Carotid Stenting and Endarterectomy: Results From the Carotid Revascularization Endarterectomy Versus Stenting Trial (2011) (186)
Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. (2006) (181)
In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. (1995) (179)
Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). (2003) (177)
One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States (2008) (175)
A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. (2005) (174)
Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United States (2010) (174)
Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. (2007) (173)
Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. (2013) (169)
TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. (2016) (167)
Bioprosthetic Valve Fracture Improves the Hemodynamic Results of Valve-in-Valve Transcatheter Aortic Valve Replacement (2017) (167)
The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. (2008) (163)
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent (2010) (162)
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (2009) (161)
Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa: Absolute Risk Versus Blood Pressure Level (2005) (160)
Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. (1993) (159)
Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve). (2014) (158)
The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. (2019) (155)
Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. (2014) (151)
Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. (2010) (151)
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention (2003) (150)
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. (2006) (148)
Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRI (2010) (145)
Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial). (2011) (145)
Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. (2013) (142)
Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). (2014) (141)
Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. (2019) (141)
Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. (1993) (141)
Cost-Effectiveness of Radiofrequency Catheter Ablation Compared With Antiarrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation (2009) (140)
Palmaz-Schatz stenting for treatment of focal vein graft stenosis: immediate results and long-term outcome. (1994) (139)
Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements. (2000) (139)
Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. (1994) (135)
Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. (1994) (134)
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. (2004) (133)
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. (2002) (132)
Use of the Kansas City Cardiomyopathy Questionnaire for Monitoring Health Status in Patients With Aortic Stenosis (2013) (130)
Improvements in Symptoms and Quality of Life in Patients With Paroxysmal Atrial Fibrillation Treated With Radiofrequency Catheter Ablation Versus Antiarrhythmic Drugs (2010) (128)
The association between blood pressure and mortality in patients with heart failure. (2006) (126)
Healthcare Resource Utilization and Costs Associated with Recurrent Episodes of Atrial Fibrillation: The FRACTAL Registry (2007) (124)
Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction. (2016) (124)
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. (2006) (123)
Can we afford to eliminate restenosis? Can we afford not to? (2004) (122)
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. (2006) (120)
Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. (2000) (120)
Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. (1996) (119)
Bioprosthetic Valve Fracture to Facilitate Transcatheter Valve-in-Valve Implantation. (2017) (119)
Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. (2016) (118)
Comparison of Clinical Interpretation With Visual Assessment and Quantitative Coronary Angiography in Patients Undergoing Percutaneous Coronary Intervention in Contemporary Practice: The Assessing Angiography (A2) Project (2013) (117)
Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis. (1998) (117)
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. (2021) (116)
Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: Results From the FREEDOM Trial (2013) (115)
Optimal Timing of Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry (2005) (115)
Economic Impact of Angina After an Acute Coronary Syndrome: Insights From the MERLIN-TIMI 36 Trial (2009) (112)
Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. (2016) (111)
A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). (2002) (109)
Troponin criteria for myocardial infarction after percutaneous coronary intervention. (2012) (109)
Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. (1998) (107)
Pericardial effusion in patients with cancer: outcome with contemporary management strategies. (1996) (106)
Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial (2000) (105)
Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results From the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial (2001) (104)
Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. (2009) (104)
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. (2016) (103)
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy (2020) (102)
Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention: Another Smoker’s Paradox? (2001) (101)
Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. (2010) (100)
Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) (2017) (99)
Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk: Results From the CoreValve US Pivotal Trial. (2015) (99)
STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. (2020) (98)
Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population: A Report From the STS/ACC Transcatheter Valve Therapy Registry (2017) (97)
Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk: Results From the PARTNER 2 Trial (2019) (96)
How to Define a Poor Outcome After Transcatheter Aortic Valve Replacement: Conceptual Framework and Empirical Observations From the Placement of Aortic Transcatheter Valve (PARTNER) Trial (2013) (94)
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. (2015) (94)
Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER 2 Randomized Clinical Trial (2017) (94)
Rethinking Composite End Points in Clinical Trials: Insights From Patients and Trialists (2014) (94)
Percutaneous treatment of protected and unprotected left main coronary stenoses with new devices: immediate angiographic results and intermediate-term follow-up. (1997) (93)
Effects of stent length and lesion length on coronary restenosis. (2004) (93)
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). (2005) (93)
Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: experience with the AngioJet catheter. (2001) (91)
Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States. (2017) (90)
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. (2005) (90)
Measuring and improving quality of care: a report from the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. (2000) (89)
Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. (2004) (89)
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. (2009) (89)
ST-segment elevation myocardial infarction (2019) (88)
Percutaneous Coronary Revascularization in Elderly Patients: Impact on Functional Status and Quality of Life (2000) (88)
Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. (1997) (88)
Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry (2010) (87)
Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. (2003) (86)
Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. (2001) (86)
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. (2008) (85)
Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison. (2017) (84)
Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction (2016) (84)
Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial* (2002) (83)
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. (2021) (83)
Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. (2016) (82)
Hospital resources consumed in treating complications associated with percutaneous coronary interventions. (2006) (82)
The limits of cost-effectiveness analysis. (2009) (82)
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial (vol 292, pg 696, 2004) (2006) (80)
Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. (2004) (80)
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. (2006) (78)
Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. (2013) (78)
Measuring and improving quality of care : A report from the american heart Association/American college of cardiology first scientific forum on assessment of healthcare quality in cardiovascular disease and stroke (2000) (77)
Cost Estimation of Cardiovascular Disease Events in the US (2011) (77)
Fractional Flow Reserve Compared With Intravascular Ultrasound Guidance for Optimizing Stent Deployment (2001) (77)
Sex-Specific Differences at Presentation and Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement (2016) (76)
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study (2015) (76)
Randomized, multicenter trial comparing sternotomy closure with rigid plate fixation to wire cerclage (2017) (75)
The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods. (2008) (75)
Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. (2003) (75)
Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. (2008) (74)
Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial. (2015) (73)
Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease: Final Results From the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial (2014) (73)
Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. (2018) (73)
Impact of Smoking on Health-Related Quality of Life After Percutaneous Coronary Revascularization (2000) (71)
Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. (2019) (71)
Admission to hospitals with on-site cardiac catheterization facilities :impact on long-term costs and outcomes. (1998) (71)
Costs and Cost-Effectiveness of Carotid Stenting Versus Endarterectomy for Patients at Standard Surgical Risk: Results From the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) (2012) (70)
Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device. (2019) (70)
Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. (2005) (70)
Bioprosthetic valve fracture: Technical insights from a multicenter study. (2019) (69)
Relation between six-minute walk test performance and outcomes after transcatheter aortic valve implantation (from the PARTNER trial). (2013) (67)
Mechanical debulking versus balloon angioplasty for the treatment of true bifurcation lesions. (1998) (67)
Ticagrelor With or Without Aspirin After Complex PCI (2020) (66)
Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results From the Evaluation of Drug Eluting Stents and Ischemic Events Registry (2008) (66)
Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention (2011) (66)
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. (2020) (65)
Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. (2015) (65)
Costs of Periprocedural Complications in Patients Treated With Transcatheter Aortic Valve Replacement: Results From the Placement of Aortic Transcatheter Valve Trial (2014) (64)
Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes. (2020) (63)
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. (2012) (63)
Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement (2018) (63)
Diagnosis and Management of Cardiovascular Disease in Advanced and End‐Stage Renal Disease (2016) (62)
Stratification of outcomes after transcatheter aortic valve replacement according to surgical inoperability for technical versus clinical reasons. (2014) (62)
Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. (2016) (61)
Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. (2021) (61)
In vivo assessment of stent expansion and recoil in normal porcine coronary arteries: differential outcome by stent design. (1999) (60)
The impact of dyspnea on health-related quality of life in patients with coronary artery disease: results from the PREMIER registry. (2009) (58)
Trends in Aortic Valve Replacement Procedures Between 2009 and 2015: Has Transcatheter Aortic Valve Replacement Made a Difference? (2018) (58)
Coronary artery stenting in the aged. (2001) (58)
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE‐ACS) obse (2017) (58)
Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). (2006) (58)
Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. (2001) (57)
Use of fractional myocardial flow reserve to assess the functional significance of intermediate coronary stenoses. (2000) (56)
Economic outcomes of percutaneous coronary intervention with drug‐eluting stents versus bypass surgery for patients with left main or three‐vessel coronary artery disease: One‐year results from the SYNTAX trial (2012) (56)
Are drug-eluting stents cost-effective? It depends on whom you ask. (2006) (56)
Cost-Effectiveness of Dual-Chamber Pacing Compared With Ventricular Pacing for Sinus Node Dysfunction (2005) (55)
Performance and Validation of the U.S. NCDR Acute Kidney Injury Prediction Model in Japan. (2016) (55)
Five-year clinical and economic outcomes among patients with medically managed severe aortic stenosis: results from a Medicare claims analysis. (2011) (54)
Effects of Ranolazine on Disease-Specific Health Status and Quality of Life Among Patients With Acute Coronary Syndromes: Results from the MERLIN-TIMI 36 Randomized Trial (2008) (54)
Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial (2019) (54)
Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year (2012) (54)
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. (2016) (54)
Development of systems of care for ST-elevation myocardial infarction patients: evaluation and outcomes. (2007) (54)
Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. (2017) (54)
Impact of Short-Term Complications on Mortality and Quality of Life After Transcatheter Aortic Valve Replacement. (2019) (54)
Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation (2020) (53)
Outcomes of inoperable symptomatic aortic stenosis patients not undergoing aortic valve replacement: insight into the impact of balloon aortic valvuloplasty from the PARTNER trial (Placement of AoRtic TraNscathetER Valve trial). (2015) (53)
Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis). (2014) (53)
Bioprosthetic Valve Fracture During Valve-in-valve TAVR: Bench to Bedside. (2017) (53)
Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). (2007) (52)
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). (2006) (52)
Stent jail: a minimum-security prison. (1996) (52)
Drug‐eluting stent task force: Final report and recommendations of the working committees on cost‐effectiveness/economics, access to care, and medicolegal issues (2004) (52)
Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy: Results From the INTERMACS Registry (2016) (51)
Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. (2001) (51)
Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program (2009) (50)
Incidence, outcomes, and effect on quality of life of cranial nerve injury in the Carotid Revascularization Endarterectomy versus Stenting Trial. (2015) (50)
Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients (2020) (49)
Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry (2011) (49)
Effect of thoracic epidural analgesia on clinical outcomes following transapical transcatheter aortic valve implantation (2012) (49)
Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial. (2016) (48)
Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use: Insights From Temporal Analysis of the Multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry (2011) (47)
Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. (2019) (47)
Ticagrelor with or without Aspirin in High-Risk Patients with Diabetes Mellitus undergoing Percutaneous Coronary Intervention. (2020) (47)
Clinical and economic outcomes after surgical aortic valve replacement in Medicare patients (2012) (47)
Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. (2016) (47)
Health-related quality of life following carotid stenting versus endarterectomy: results from the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at HIgh Risk for Endarterectomy) trial. (2010) (47)
Five-year Clinical and Economic Outcomes Among Patients With Medically Managed Severe Aortic Stenosis: Results From a Medicare Claims Analysis (2012) (46)
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. (2002) (45)
Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. (2007) (45)
Costs and cost‐effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: Results from the SAPPHIRE trial (2011) (45)
Transcarotid Versus Transapical and Transaortic Access for Transcatheter Aortic Valve Replacement. (2019) (45)
The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry: rationale and design (2017) (44)
Impact of Bleeding on Quality of Life in Patients on DAPT: Insights From TRANSLATE-ACS. (2016) (44)
Inclusion of Functional Status Measures in the Risk Adjustment of 30-Day Mortality After Transcatheter Aortic Valve Replacement: A Report From the Society of Thoracic Surgeons/American College of Cardiology TVT Registry. (2018) (44)
Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement: Report From the STS/ACC TVT Registry (2015) (43)
Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. (2019) (43)
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during PCI: An analysis from the REPLACE-2 trial (2004) (43)
Causes of late mortality with dual antiplatelet therapy after coronary stents. (2015) (43)
Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention (2012) (43)
Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial. (2017) (43)
Clinical and Economic Outcomes of Percutaneous Coronary Interventions in the Elderly: An Analysis of Medicare Claims Data (2004) (43)
Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. (2018) (43)
Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. (2004) (43)
ACCF/AHA Methodology for the Development of Quality Measures for Cardiovascular Technology: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (2011) (43)
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. (2006) (42)
Global Variation in the Prevalence of Elevated Cholesterol in Outpatients With Established Vascular Disease or 3 Cardiovascular Risk Factors According to National Indices of Economic Development and Health System Performance (2012) (42)
Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial (2003) (41)
Short- and Intermediate-Term Clinical Outcomes From Direct Myocardial Laser Revascularization Guided by Biosense Left Ventricular Electromechanical Mapping (2000) (41)
The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry. (2012) (41)
Variation in Hospital Risk–Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (2016) (41)
Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry). (2009) (40)
The carotid artery revascularization and endarterectomy (CARE) registry: Objectives, design, and implications (2008) (40)
Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial. (2015) (40)
Cost-Effectiveness of Targeting Patients Undergoing Percutaneous Coronary Intervention for Therapy With Bivalirudin Versus Heparin Monotherapy According to Predicted Risk of Bleeding (2010) (39)
Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis. (2020) (39)
Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. (2006) (39)
Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. (2019) (39)
Clinical correlates of in-hospital costs for acute myocardial infarction in patients 65 years of age and older. (1998) (39)
Incidence and predictors of myocardial infarction among patients with atrial fibrillation. (2000) (38)
Rotational atherectomy or balloon angioplasty in the treatment of intra‐stent restenosis: BARASTER Multicenter Registry (2000) (38)
Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial. (2019) (38)
Sex-Specific Outcomes of Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve: Insights From the PARTNER II S3 High-Risk and Intermediate-Risk Cohorts. (2018) (38)
Impact of subintimal plaque modification procedures on health status after unsuccessful chronic total occlusion angioplasty (2018) (38)
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. (1999) (37)
Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions). (2016) (37)
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. (2006) (37)
Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience. (2003) (37)
The Effect and Relationship of Frailty Indices on Survival After Transcatheter Aortic Valve Replacement. (2020) (37)
Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. (2004) (37)
Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease (2017) (36)
Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry. (2015) (36)
Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. (2006) (35)
Cost-Effectiveness of Gamma Radiation for Treatment of In-Stent Restenosis: Results From the Gamma-1 Trial (2002) (35)
Effectiveness of rheolytic coronary thrombectomy with the AngioJet catheter. (2002) (35)
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. (2015) (35)
Transcatheter Mitral Valve Therapy in the United States: A Report From the STS-ACC TVT Registry. (2021) (35)
Technical feasibility , safety , and clinical outcome of stenting of unprotected left main coronary artery bifurcation narrowing (34)
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. (2009) (34)
Quality of life among patients with severe aortic stenosis (2012) (34)
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. (2012) (34)
Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfu (2006) (34)
Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement (2021) (34)
Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Diabetes: Insights From the OPEN CTO Registry. (2017) (33)
Prevalence and Outcomes of Isolated Tricuspid Valve Surgery Among Medicare Beneficiaries. (2019) (33)
Do Differences in Repeat Revascularization Explain the Antianginal Benefits of Bypass Surgery Versus Percutaneous Coronary Intervention?: Implications for Future Treatment Comparisons (2012) (33)
Selecting Antiplatelet Therapy at the Time of Percutaneous Intervention for an Acute Coronary Syndrome: Weighing the Benefits and Risks of Prasugrel Versus Clopidogrel (2013) (33)
Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. (2016) (33)
Race and Sex Differences in Post–Myocardial Infarction Angina Frequency and Risk of 1-Year Unplanned Rehospitalization (2017) (32)
Concordance of physician ratings with the appropriate use criteria for coronary revascularization. (2011) (32)
Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. (1999) (31)
Multivessel Palmaz-Schatz stenting: early results and one-year outcome. (1997) (31)
Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year: Analysis of the Transcatheter Valve Therapy Registry (2018) (31)
Is 40% to 70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? (1994) (31)
Survival Benefit With Drug-Eluting Stents in Observational Studies: Fact or Artifact? (2011) (31)
Cost-Effectiveness of Drug-Eluting Stents Versus Bare Metal Stents in Clinical Practice (2011) (31)
Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: Results from the randomized SIRIUS trial (2003) (30)
Cost‐Effectiveness of Supervised Exercise, Stenting, and Optimal Medical Care for Claudication: Results From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Trial (2014) (30)
Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China (2018) (30)
Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. (2005) (30)
Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events. (2008) (29)
Impact of drug eluting stent length on outcomes of percutaneous coronary intervention (from the EVENT registry). (2012) (29)
Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. (1999) (29)
Variation in post‐TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry (2018) (29)
Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. (2013) (29)
Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation: The COAPT Trial. (2020) (29)
Cost Effectiveness of the Sirolimus-Eluting Stent in High-Risk Patients in Canada (2006) (29)
Durability of quality of life benefits of transcatheter aortic valve replacement: Long‐term results from the CoreValve US extreme risk trial (2017) (29)
Heparin-induced thrombocytopenia and thrombosis. (1998) (28)
Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. (2020) (28)
No "i" in Heart Team: incentivizing multidisciplinary care in cardiovascular medicine. (2012) (28)
Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization (2004) (28)
Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories. (2000) (28)
Prediction of residual angina after percutaneous coronary intervention. (2015) (28)
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. (2021) (28)
In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascuCoil Trial). (2004) (27)
Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: Results From a Propensity Score–Matched Analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry (2011) (26)
Impact of calcification on percutaneous coronary intervention: MACE‐Trial 1‐year results (2019) (26)
In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. (2002) (26)
Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial (2013) (26)
Origin of the left main coronary artery from the "non-coronary" sinus of Valsalva. (1991) (26)
Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. (2011) (26)
In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty: Insights From the OPEN-CTO Registry. (2019) (26)
Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population (2018) (26)
Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE‐ACS Study (2017) (25)
Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry®–Get With The Guidelines (GWTG)® (2017) (25)
Cost-effectiveness of transcatheter valvular interventions: economic challenges. (2013) (25)
Current clinical characteristics and economic impact of subacute stent thrombosis. (2002) (25)
The impact of optimal stenting techniques on cardiac catheterization laboratory resource utilization and costs. (1997) (25)
Health after coronary stenting or balloon angioplasty: results from the Stent Restenosis Study. (1997) (25)
Hospital Practice of Direct‐Home Discharge and 30‐Day Readmission After Transcatheter Aortic Valve Replacement in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry (2017) (24)
The impact of bivalirudin on percutaneous coronary intervention-related bleeding. (2010) (24)
Impact of a Claims-Based Frailty Indicator on the Prediction of Long-Term Mortality After Transcatheter Aortic Valve Replacement in Medicare Beneficiaries (2018) (24)
Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement: The STS/ACC TVT Registry. (2019) (24)
Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions. (2021) (23)
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry) (2017) (23)
The Norwood operation: Relative effects of surgeon and institutional volumes on outcomes and resource utilization (2015) (23)
Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina (2019) (23)
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. (2015) (23)
Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent (2002) (22)
Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: The National Cardiovascular Data Registry CathPCI Registry (2019) (22)
Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. (2003) (22)
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. (2017) (22)
Temporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement: A Placement of AoRTic TraNscathetER Valve (PARTNER) Trial Substudy (2015) (22)
Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure (2021) (22)
Complications of Bioprosthetic Valve Fracture as an Adjunct to Valve-in-Valve TAVR (2019) (21)
Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? (2014) (21)
Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) (2018) (21)
Patients overestimate the potential benefits of elective percutaneous coronary intervention. (2012) (20)
Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER S3i Trial. (2018) (20)
Hospital Variation in the Utilization of Short-Term Nondurable Mechanical Circulatory Support in Myocardial Infarction Complicated by Cardiogenic Shock (2019) (20)
Impact of Short-Term Complications of TAVR on Longer-Term Outcomes: Results from the STS/ACC Transcatheter Valve Therapy Registry. (2020) (19)
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and (2016) (19)
Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients (2017) (19)
Impact of Transcatheter Aortic Valve Durability on Life Expectancy in Low-Risk Patients With Severe Aortic Stenosis (2020) (19)
Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. (2007) (18)
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial (2017) (18)
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. (2021) (18)
NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: The COAPT Trial. (2020) (18)
Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial (2020) (18)
Cost-effectiveness of prasugrel in a US managed care population (2012) (18)
Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. (2016) (18)
Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial. (2001) (18)
Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. (2019) (17)
Surgical Versus Percutaneous Femoral Access for Delivery of Large-Bore Cardiovascular Devices (from the PARTNER Trial). (2016) (17)
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia (2003) (17)
Cost-Effectiveness of Percutaneous Coronary Intervention with Drug-Eluting Stents vs. Bypass Surgery for Patients with 3-Vessel or Left Main Coronary Artery Disease: Final Results from the SYNTAX Trial (2014) (17)
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. (2017) (17)
Claudication: exercise vs endoluminal revascularization (CLEVER) study update. (2009) (17)
Long‐term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3‐year results from the STROLL study (2018) (16)
Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents (2020) (16)
Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). (2018) (16)
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. (2021) (16)
Carotid artery stenting of a contralateral occlusion and in-hospital outcomes: results from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. (2013) (16)
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study (2016) (16)
Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease. (2019) (16)
Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the ‘real world’ (2008) (16)
Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome Prospective Open Label Antiplatelet Therapy Study (2015) (15)
Rheolytic thrombectomy and platelet glycoprotein IIb/IIIa blockade for stent thrombosis (2002) (15)
Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective (2015) (15)
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. (2021) (15)
Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials (2000) (15)
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. (2016) (15)
Multivessel drug‐eluting stenting and impact of diabetes mellitus—A report from the EVENT registry (2009) (15)
Health Status Changes and Outcomes in Patients with Heart Failure and Mitral Regurgitation: From COAPT. (2020) (15)
Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention (2019) (15)
Rigid Plate Fixation Versus Wire Cerclage: Patient-Reported and Economic Outcomes From a Randomized Trial. (2018) (15)
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial. (2003) (14)
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial) (2003) (14)
Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non–ST-Segment–Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events Registry (2014) (14)
Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement. (2022) (14)
Modeling the impact of patient and lesion characteristics on the cost-effectiveness of drug-eluting stents (2003) (14)
Analysis of early out-of hospital mortality after transcatheter aortic valve implantation among patients with aortic stenosis successfully discharged from the hospital and alive at 30 days (from the placement of aortic transcatheter valves trial). (2014) (14)
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention (2020) (14)
Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus (2009) (14)
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry (2016) (13)
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. (2016) (13)
Relationship of Albuminuria and Renal Artery Stent OutcomesNovelty and Significance (2016) (13)
Multivessel Versus Culprit Vessel–Only Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction: Insights From the TRANSLATE‐ACS Observational Study (2017) (13)
Cost-effectiveness of coronary interventions (1997) (13)
Correlation of patient-reported symptom outcomes and treadmill test outcomes after treatment for aortoiliac claudication. (2013) (13)
The influence of diabetes mellitus on the practice and outcomes of percutaneous coronary intervention in the community: a report from the HCA database. (2003) (13)
Association of Statin Use and Mortality After Transcatheter Aortic Valve Replacement (2019) (12)
Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing Transcatheter Aortic Valve Replacement (2018) (12)
Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. (2010) (12)
Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of Drug Eluting Stents and Ischemic Events registry. (2011) (12)
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluation of the cost-effectiveness of coronary stenting: a societal perspective. (1999) (12)
Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronar (2017) (12)
Impact of multivessel revascularization on health status outcomes in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. (2015) (12)
Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). (2014) (12)
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (2009) (12)
Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry (2019) (12)
The PARTNER 3 Bicuspid Registry for Transcatheter Aortic Valve Replacement in Low-Surgical-Risk Patients. (2022) (12)
Resource utilization, cost, and health status impacts of coronary stent versus "optimal" percutaneous coronary angioplasty: results from the OPUS-I trial. (2002) (11)
Very early changes in quality of life after transcatheter aortic valve replacement: Results from the 3M TAVR trial. (2020) (11)
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. (2019) (11)
ACCF/AHA methodology for the development of quality measures for cardiovascular technology: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures. (2011) (11)
Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI: An ADAPT-DES Substudy. (2022) (11)
Clinical and economic effects of coronary restenosis after percutaneous coronary intervention in a managed care population. (2005) (11)
Safety of subxyphoid pericardial access using a blunt-tip needle. (2002) (11)
Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST (2017) (11)
Is Bioprosthetic Valve Fracture Beneficial for Patients with Larger Surgical Valves Undergoing Valve in Valve TAVR? (2018) (11)
Association between health status and long‐term mortality after percutaneous revascularization of peripheral artery disease (2016) (10)
Predicting long‐term bleeding after percutaneous coronary intervention (2017) (10)
Appropriate patient selection or health care rationing? Lessons from surgical aortic valve replacement in the Placement of Aortic Transcatheter Valves I trial. (2015) (10)
Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012-2018. (2021) (10)
Practice and outcomes of percutaneous coronary intervention in the community before drug-eluting stents: a report from the HCA database. (2003) (10)
Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial. (2019) (10)
Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. (2017) (10)
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). (2017) (10)
Economic Implications of Transcatheter Aortic Valve Replacement in Patients at Intermediate Surgical Risk. (2016) (10)
Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. (2020) (10)
Integrating Quality of Life and Survival Outcomes Cardiovascular Clinical Trials. (2019) (10)
When is better not good enough?: Insights from the COURAGE economic study. (2008) (10)
Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN‐CTO registry (2020) (10)
Health-Related Quality of Life After Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis (2012) (10)
Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation: The COAPT Trial. (2020) (10)
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study (2017) (10)
Impact of Local Anesthesia Only Versus Procedural Sedation Using the Vancouver Clinical Pathway for TAVR: Insights From the 3M TAVR Study. (2019) (10)
Health Status Benefits of Successful Chronic Total Occlusion Revascularization Across the Spectrum of Left Ventricular Function: Insights From the OPEN-CTO Registry. (2018) (10)
Comparing Cost-Utility Analyses in Cardiovascular Medicine (2003) (9)
Coronary stenting: costly or cost-effective? (1995) (9)
Heparin use for diagnostic cardiac catheterization with a radial artery approach: An international survey of practice patterns (2018) (9)
Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. (2014) (9)
Cost-effectiveness of oral antiplatelet agents—current and future perspectives (2011) (9)
Age and Outcomes following Stenting compared to Endarterectomy: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) (2011) (9)
Prevalence and predictors of persistent health status impairment in patients referred to a vascular clinic with intermittent claudication. (2011) (9)
Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. (2021) (9)
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. (2017) (9)
Trends in isolated aortic valve replacement in the United States in the early phase of expansion of TAVR. (2019) (8)
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial. (2017) (8)
Predicting Likelihood for Coronary Artery Bypass Grafting After Non-ST-Elevation Myocardial Infarction: Finding the Best Prediction Model. (2016) (8)
Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. (2017) (8)
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. (2021) (8)
Willingness To Pay To Eliminate the Risk of Restenosis Following Percutaneous Coronary Intervention: A Contingent Valuation (2011) (8)
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes Vytorin Efficacy International Trial) (2017) (8)
Transcatheter Aortic Valve Replacement in Low-Population Density Areas (2020) (8)
Does stenting save lives? Understanding the strengths and limitations of meta-analysis. (2004) (8)
Balloon postdilation can safely improve the results of successful (but suboptimal) directional coronary atherectomy. (1993) (8)
Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). (2012) (7)
Understanding Readmissions in Medicare Beneficiaries During the 90‐Day Follow‐Up Period of an Acute Myocardial Infarction Admission (2019) (7)
In‐Hospital and 1‐year outcomes with drug‐eluting versus bare metal stents in saphenous vein graft intervention: A report from the EVENT registry (2012) (7)
Do the benefits of new technology outweigh the costs? (2003) (7)
Exploring the Reduction in Hospitalization Costs Associated with Next-Day Discharge following Transfemoral Transcatheter Aortic Valve Replacement in the United States (2019) (7)
Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial. (2005) (7)
Predicting the EQ-5D from the Kansas City Cardiomyopathy Questionnaire (KCCQ) in Patients with Heart Failure. (2021) (7)
Deep Learning Electrocardiographic Analysis for Detection of Left-Sided Valvular Heart Disease. (2022) (7)
TRENDS IN CORONARY REVASCULARIZATION PROCEDURES AMONG MEDICARE BENEFICIARIES BETWEEN FISCAL YEARS 2008 AND 2010 (2012) (7)
Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization (2016) (7)
Composite Metric for Benchmarking Site Performance in Transcatheter Aortic Valve Replacement (2021) (7)
Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial. (2020) (7)
Rotational atherectomy for the treatment of restenotic ostial side branches jailed by prior stent placement. (1998) (7)
Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. (2019) (7)
Prognostic Impact of Subsequent Acute Coronary Syndrome and Unplanned Revascularization on Long‐Term Mortality After an Index Percutaneous Coronary Intervention: A Report From a Japanese Multicenter Registry (2017) (7)
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). (2003) (7)
In‐hospital and one year outcomes with drug‐eluting versus bare metal stents in large native coronary arteries: A report from the evaluation of drug‐eluting stents and ischemic events registry (2013) (7)
Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. (2010) (6)
1-Year Outcomes following Bioprosthetic Valve Fracture to Facilitate Valve-in-Valve Transcatheter Aortic Valve Replacement (2021) (6)
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk: A Cost Consequence Simulation From PARIS (2019) (6)
Practical Application of Patient-Reported Health Status Measures for Transcatheter Valve Therapies (2021) (6)
Change in Hospitalization Rates Following Transcatheter Mitral Valve Repair: A Nationwide Cohort Sample. (2019) (6)
Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes The (2019) (6)
Analysis of Adverse Events Related to Impella® Usage (From the Manufacturer and User Facility Device Experience and National Inpatient Sample Databases). (2020) (6)
Readmission for Acute Decompensated Heart Failure among Patients Successfully Treated with Transcatheter Aortic Valve Replacement: A PARTNER-1 Substudy (2018) (6)
P he Frequency and Incremental Cost of Major omplications Among Medicare Beneficiaries eceiving Implantable Cardioverter-Defibrillators (2006) (6)
Association of Stress Test Risk Classification With Health Status After Chronic Total Occlusion Angioplasty (from the Outcomes, Patient Health Status and Efficiency in Chronic Total Occlusion Hybrid Procedures [OPEN-CTO] Study). (2017) (6)
Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. (2009) (6)
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). (2011) (6)
Drug eluting stents for ST-elevation myocardial infarction: risk and benefit (2007) (6)
Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. (2015) (5)
#SoMe for #IC: Optimal use of social media in interventional cardiology (2021) (5)
TCT-36 Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial. (2016) (5)
Impact of Frailty and Prefrailty on Outcomes of Transcatheter or Surgical Aortic Valve Replacement. (2022) (5)
TCT-118 A Multidisciplinary, Multimodality, But Minimalist (3M) Approach To Transfemoral Transcatheter Aortic Valve Replacement Facilitates Safe Next Day Discharge In High Risk Patients (2013) (5)
Impact of the Food and Drug Administration's Public Health Notification on the adoption of drug-eluting stents. (2007) (5)
Longevity of the placebo effect in patients enrolled in angiogenesis and laser myocardial revascularization trials (2002) (5)
Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial. (2019) (5)
THE IMPACT OF SIX–MINUTE WALK TEST PERFORMANCE ON OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: INSIGHTS FROM THE PARTNER TRIAL (2013) (5)
Percutaneous Coronary Intervention: Finally Mature Enough. (2015) (5)
Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study. (2021) (5)
Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. (2021) (5)
Variation in Practice Regarding Pretreatment With Dual Antiplatelet Therapy for Patients With Non–ST Elevation Myocardial Infarction (2016) (5)
Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial. (2011) (5)
Left ventricular global longitudinal strain in patients with moderate aortic stenosis. (2022) (4)
Unmeasured, unknown, and hidden: Confounders are not always in plain sight. (2020) (4)
Abstract 16534: Cost-Effectiveness of Edoxaban vs. Warfarin in Patients With Atrial Fibrillation: Results From the ENGAGE AF - TIMI 48 Economic Study (2014) (4)
Extravasation of thrombus into the aortic root: a complication following use of an infusion catheter for intragraft thrombolysis. (1996) (4)
CONSCIOUS SEDATION VERSUS GENERAL ANESTHESIA FOR TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS OF AN INSTRUMENTAL VARIABLE ANALYSIS (2020) (4)
The effect of institutional experience on the outcome of primary angioplasty for acute MI (1996) (4)
A Composite Metric for Benchmarking Site Performance in TAVR: Results from the STS/ACC TVT Registry. (2021) (4)
1040-71 Interhospital transfers are costly, cause delays and do not address the imbalance of access to revascularization: The case for more angiographic facilities? Results from the global registry of acute coronary events (2004) (4)
Relationship between stent type and quality of life after percutaneous coronary intervention for acute myocardial infarction. (2015) (4)
Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. (2007) (4)
Cost implications of intraprocedural thrombotic events during PCI (2015) (4)
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 Trial (2020) (4)
Factors Associated With and Outcomes of Aborted Procedures During Elective Transcatheter Aortic Valve Replacement. (2019) (4)
Combined Transcatheter Aortic Valve Replacement and Thoracic Endovascular Aortic Repair Using Transapical Access. (2015) (4)
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI (2022) (4)
Balloon angioplasty versus debulking for treatment of diffuse in-stent restenosis (1998) (4)
The cost-effectiveness of transcatheter aortic valve replacement for nonsurgical candidates: revisionist history or the final word? (2013) (4)
Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement (2021) (4)
Anti-Anginal Medication Titration Among Patients with Residual Angina 6-Months After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from OPEN CTO Registry. (2018) (4)
Abstract 15573: In-Hospital Switching of ADP Receptor Inhibitors in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study (2012) (4)
Pre- Versus Post-Procedure Health Care Resource Utilization in Patients Undergoing Commercial Transcatheter Mitral Valve Repair. (2019) (4)
Orthopedic Principles to Facilitate Enhanced Recovery After Cardiac Surgery. (2020) (3)
Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry. (2020) (3)
REDUCING THE COST OF TAVR: AN EVALUATION OF THE IMPACT OF LENGTH OF STAY ON THE COST OF TRANSCATHETER AORTIC VALVE REPLACEMENT (2014) (3)
Association Between Diastolic Dysfunction and Health Status Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. (2019) (3)
Utilization, Costs, and Outcomes of Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement (2021) (3)
Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes (2020) (3)
Impact of Complications on Resource Utilization During 90-Day Coronary Artery Bypass Graft Bundle for Medicare Beneficiaries. (2019) (3)
Bioprosthetic Valve Remodeling of Trifecta Surgical Valves to Facilitate Valve-in-Valve TAVR (2020) (3)
TCT-691 Sex-Specific Differences After Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients: An Analysis from the PARTNER 2 Randomized Trial. (2016) (3)
IS MULTI-VESSEL PRIMARY PCI ADVISABLE? DIFFERENCES IN CLINICAL OUTCOMES AMONG MEDICARE BENEFICIARIES UNDERGOING SINGLE VERSUS MULTI-VESSEL PCI DURING A PRIMARY ST-SEGMENT ELEVATED MYOCARDIAL INFARCTION HOSPITALIZATION IN FISCAL YEAR 2007 (2010) (3)
Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. (2015) (3)
Abstract P233: Selecting Antiplatelet Therapy After Percutaneous Intervention for an Acute Coronary Syndrome: Weighing the Risks and Benefits of Prasugrel Versus Clopidogrel (2011) (3)
Comparison of Effects of Abciximab Versus Eptifibatide on C-Reactive Protein, Interleukin-6, and Interleukin- 1 Receptor Antagonist After Coronary Arterial Stenting (2003) (3)
The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale. (2019) (3)
External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI. (2022) (3)
709-4 Intraaortic Balloon Pump Counterpulsation in Octogenarians: Outcome and Complications (1995) (3)
Appropriate Use Criteria and Health Status Outcomes Following Chronic Total Occlusion Percutaneous Coronary Intervention (2020) (3)
Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: COAPT Trial. (2021) (3)
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry (2019) (3)
Statistical primer: a cost-effectiveness analysis. (2018) (3)
Cost-Effectiveness of Percutaneous Coronary Intervention Versus Bypass Surgery for Patients With Left Main Disease: Results From the EXCEL Trial (2022) (3)
TCT-701 A Multidisciplinary, Multimodality, but Minimalist (3M) approach to transfemoral transcatheter aortic valve replacement facilitates safe next day discharge home in high risk patients: 1 year follow up (2014) (3)
Ultra-low-contrast angiography in patients with advanced chronic kidney disease and previous coronary artery bypass surgery (2019) (3)
An evidence-based approach to the use of drug-eluting stents in clinical practice. (2004) (3)
Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions (2021) (3)
The Role of Frailty in Identifying Benefit from Transcatheter Versus Surgical Aortic Valve Replacement. (2021) (3)
Vision and Creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers (2009) (3)
Cost-effectiveness of TAVR in low-risk patients: do we have more than a NOTION? (2019) (3)
ASSOCIATION OF STENT THROMBOSIS AND PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS: SIX MONTH RESULTS OF THE PARIS REGISTRY (2012) (2)
Abstracts - ACCIS2002 (angiography & interventional cardiology)Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial (2002) (2)
Transradial Percutaneous Coronary Intervention... Works Great! Less Billing! (2018) (2)
Prognostic value of left ventricular ejection fraction and symptom severity in patients with moderate aortic stenosis (2021) (2)
Embolic Protection Devices in Saphenous Vein Graft Intervention. (2019) (2)
Treatment of diffuse coronary lesions: a time for randomized trials. (1999) (2)
Costs and effects of stent implantation versus balloon angioplasty (1998) (2)
Benchmarking cardiac catheterization laboratories: the impact of patient age, gender and risk factors on variable costs, device costs, total time and procedural time in 53 catheterization laboratories. (1999) (2)
1003-94 Rheolytic thrombectomy for the treatment of acute myocardial infarction in patients with angiographic large thrombus burden: One-year results of the VeGAS 2 acute myocardial infarction registry (2004) (2)
Cost-effectiveness of abciximab after coronary stenting: a decision-analytic model (1998) (2)
Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial (2021) (2)
Impact of Transcatheter Mitral Valve Repair Availability on Volume and Outcomes of Surgical Repair. (2023) (2)
PERIPHERAL VERSUS CENTRAL ACCESS FOR ALTERNATIVE ACCESS TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR): RESULTS FROM THE TVT REGISTRY (2020) (2)
COSTS OF PERIPROCEDURAL COMPLICATIONS IN PATIENTS TREATED WITH TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS FROM THE PARTNER TRIAL (2014) (2)
The CLEVER ( Claudication : Exercise Vs . Endoluminal Revascularization ) Study : Rationale and Methods (2008) (2)
90-DAY COST AND CLINICAL OUTCOMES COMPARING TAVR TO SAVR: DO THE ECONOMICS WORK? (2018) (2)
Integrating Quality of Life and Survival Outcomes Cardiovascular Clinical Trials: Results from the PARTNER Trial (2019) (2)
Drug-eluting stents for ST[corrected]-elevation acute myocardial infarction: do we need randomized trials? (2006) (2)
PERIPHERAL ARTERY DISEASE AND TRANSCATHETER AORTIC VALVE REPLACEMENT OUTCOMES: A REPORT FROM THE STS/TVT REGISTRY (2017) (2)
Health Services and Outcomes Research Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis (2012) (2)
Identification of Frailty Using a Claims‐Based Frailty Index in the CoreValve Studies: Findings from the EXTEND‐FRAILTY Study (2021) (2)
Economic implications of bivalirudin in the cardiac catheterization laboratory. (2006) (2)
Cardiovascular Perspectives The Limits of Cost-Effectiveness Analysis (2009) (2)
TCT-756 Incidence, Predictors, and Prognostic Impact of Late Bleeding (≥30 days) Complications after Transcatheter Aortic Valve Replacement (TAVR) (2014) (2)
Patient Risk Assessment for Transcatheter Aortic Valve Replacement at Veterans Health Administration Hospitals. (2020) (2)
Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial (2002) (2)
Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement (2020) (2)
Why Is Intravascular Ultrasound Guidance Underutilized in Percutaneous Coronary Intervention?: It Is Not "All About the Benjamins". (2021) (2)
Association of Smoking Status With Long‐Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (2019) (2)
Intravenous Acetaminophen Improves Outcomes After Transapical Transcatheter Aortic Valve Replacement (2018) (2)
INDEPENDENT US VALIDATION OF THE BRITISH COLUMBIA PCI RISK SCORE (2010) (1)
Real-World Cost Effectiveness Of The Mitraclip For The Treatment Of High-Risk Mitral Regurgitation (2014) (1)
5-YEAR HEALTH STATUS OUTCOMES AFTER SELF-EXPANDING TRANSCATHETER OR SURGICAL AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH SEVERE AORTIC STENOSIS (2020) (1)
AF Ablation Outcomes: Real World or Fun House Mirror? (2020) (1)
Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction (2016) (1)
Abstract 314: Impact of Spontaneous Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial (2014) (1)
A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. (2008) (1)
The impact of diabetes on clinical and economic outcomes of percutaneous coronary intervention in the elderly: A population-based analysis (2003) (1)
Abstract 4557: Mode of Death After Contemporary Percutaneous Coronary Intervention: A Report From the EVENT Multicenter Registry (2009) (1)
COMPARATIVE EFFECTIVENESS OF BLEEDING AVOIDANCE THERAPIES IN PCI PATIENTS: ANALYSIS FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY® (2010) (1)
Site-Level Variability in 30-Day Patient Outcomes After Transcatheter Mitral Valve Repair in the United States (2020) (1)
ASSOCIATION BETWEEN SHORT-TERM HEALTH STATUS CHANGES AND LONG-TERM CLINICAL OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR VS. MEDICAL THERAPY IN PATIENTS WITH HEART FAILURE AND FUNCTIONAL MITRAL REGURGITATION: THE COAPT TRIAL (2020) (1)
TCT-892 Predictors of “futility” with transcutaneous aortic valve replacement therapy (TAVR): An analysis from the PARTNER randomized trial (2012) (1)
Abstract 13035: Impact of Ezetimibe on Hospitalization-Related Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (2015) (1)
Abstract 13201: 5-Year Quality of Life Outcomes After CABG vs. PCI among Patients With 3-Vessel or Left Main Coronary Disease: Results From the SYNTAX Trial (2013) (1)
TCT-2 Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: 30-Day Outcomes from the TRANSLATE-ACS Observational Study (2013) (1)
IMPACT OF LEVEL OF ANAESTHESIA USING THE VANCOUVER CLINICAL PATHWAY FOR TRANSCATHETER AORTIC VALVE REPLACEMENT: INSIGHTS FROM THE 3M TAVR STUDY (2018) (1)
Unraveling the pathophysiology of percutaneous coronary intervention: is it in the genes? (2000) (1)
TCT-831 Biodegradable-Polymer Drug-Eluting Stents versus Bare Metal Stents versus Durable-Polymer Drug-Eluting Stents : A Systematic Review and Bayesian Approach Network Meta-Analysis (2013) (1)
Cost-effectiveness of alternative approaches to the management of chronic obstructive coronary artery disease. (2009) (1)
COST EFFECTIVENESS OF EVEROLIMUS- VS. PACLITAXEL-ELUTING STENTS FOR PATIENTS UNDERGOING PERCUTANEOUS CORONARY REVASCULARIZATION. 2-YEAR RESULTS FROM THE SPIRIT-IV TRIAL (2011) (1)
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. (2022) (1)
PREDICTORS OF POOR OUTCOME AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT IN THE PARTNER TRIAL (2013) (1)
POOR OUTCOME AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: ASSOCIATIONS OF MORTALITY AND QUALITY OF LIFE WITH FRAILTY IN THE PARTNER TRIAL (2015) (1)
In-hospital outcomes and cost comparison of femoropopliteal reopening strategies. (2011) (1)
De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status. (2019) (1)
Abstract 316: Costs Of Contrast Induced Acute Kidney Injury (2013) (1)
PREDICTING THE LIKELIHOOD FOR CORONARY ARTERY BYPASS GRAFTING IN NON ST ELEVATION MYOCARDIAL INFARCTION PATIENTS (2015) (1)
Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials. (2023) (1)
Abstract 314: Institution-level Variability in 30-day Patient Outcomes After Transcatheter Mitral Valve Repair in The United States (2020) (1)
Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial. (2022) (1)
SEX–SPECIFIC DIFFERENCES IN LATE MORTALITY AFTER TRANSCATHETER AVR IN THE PARTNER TRIAL (2013) (1)
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age (1)
Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. (2018) (1)
DIRECT ILIAC ARTERY PUNCTURE DURING ENDOVASCULAR PROCEDURES: ARE CONDUITS REALLY NECESSARY? (2014) (1)
ROUTINE EARLY DISCHARGE AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A PROPENSITY SCORE ANALYSIS FROM THE PARTNER 2 SAPIEN 3 STUDY (2018) (1)
Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis. (2020) (1)
Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial (2021) (1)
Abstract 3855: Cost-Effectiveness of Clopidogrel + Aspirin vs. Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial (2006) (1)
TCT-494 Safety and Effectiveness of Prasugrel vs. Clopidogrel in the Setting of Bivalirudin vs. Heparin Use: 30-day Results from TRANSLATE-ACS (2014) (1)
PATTERNS OF ADHERENCE TO DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING COMPLEX PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE PARIS REGISTRY (2015) (1)
Valve-in-valve TAVR using the SAPIEN 3 transcatheter heart valve: still plagued by patient-prosthesis mismatch. (2018) (1)
Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial. (2021) (1)
CRT-200.46 Impact of Coronary Calcification on Clinical Outcomes and Health Care Related Costs Among Elderly Patients Undergoing Percutaneous Coronary Intervention (2016) (1)
Patient Characteristics Associated With Antianginal Medication Escalation and De-Escalation Following Chronic Total Occlusion Percutaneous Coronary Intervention. (2019) (1)
PCV87 COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND PLANNED PCI: RESULTS FROM THE TRITON-TIMI 38 TRIAL FROM THE GERMAN PERSPECTIVE (2009) (1)
A MULTIDISCIPLINARY, MULTIMODALITY, BUT MINIMALIST (3M) APPROACH TO TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT FACILITATES SAFE NEXT DAY DISCHARGE HOME IN HIGH RISK PATIENTS: 1 YEAR FOLLOW UP (2014) (1)
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness afterMyocardial Infarction Study ( ARTEMIS ) : A multicenter , cluster-randomized trial of P 2 Y 12 receptor inhibitor copayment reduction after myocardial infarction (2016) (1)
Abstract 11: Comparison of Patient Reported Angina with Provider Assigned Canadian Cardiovascular Society Angina Class Before and After Revascularization (2016) (1)
TAVR After Prior Mitral Valve Surgery: Results from the Transcatheter Valve Therapy Registry. (2020) (1)
Abstract 15002: Hospital Strategies to Address Non-Adherence to Guideline-Recommended Dual Antiplatelet Therapy After Myocardial Infarction: Findings From the Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS) (2016) (1)
ASSOCIATION OF DISEASE-SPECIFIC HEALTH STATUS WITH LONG-TERM MORTALITY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (2015) (1)
Timing and risk factors for enzymatic myocardial infarctions in patients undergoing percutaneous intervention: Insights from TARGET (2003) (1)
Moderated PosterTAVR EconomicsTCT-242 Cost Savings Associated with Next-day Discharge among US Medicare Beneficiaries Undergoing Transcatheter Aortic Valve Replacement (2017) (1)
PROSTHETIC SURGICAL TISSUE VALVE ENLARGEMENT USING A HIGH-PRESSURE BALLOON (FRACTURING THE RING) TO FACILITATE TRANSCATHETER VALVE-IN-VALVE IMPLANTATION (2017) (1)
Comparison of procedural complications with versus without interventional cardiology fellows-in-training during contemporary percutaneous coronary intervention. (2014) (1)
TCT-621 Drug-Eluting Stent Event Registry of Thrombosis (DESERT): The International Drug-Eluting Stent Thrombosis Registry, Angiographic Assessment (2012) (1)
TCT-95 Outcomes of Transcatheter vs. Surgical Aortic Valve Replacement in Women: Insights from the Randomized PARTNER Trial (2012) (1)
Contemporary use of dual antiplatelet therapy for preventing cardiovascular events. (2014) (1)
Abstract P271: Mortality Benefit With Drug-Eluting Stents in Observational Studies: Fact or Artifact? Insights From the Prospective, Multicenter EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry (2011) (1)
Abstract 354: Large Variation In Contrast Use During PCI - An Important Opportunity For Reducing Acute Kidney Injury (2013) (1)
TCT-225 Impact of frailty on a minimalist approach and early discharge following TAVR: insights from the 3M TAVR Study (2018) (1)
TCT-117 Quality of Life Outcomes Among High-Risk Patients Undergoing TAVR via the Transapical Approach: A PARTNER Continued Access Substudy (2013) (0)
Abstract 15991: Assessing Longitudinal Medication Use in Pragmatic Clinical Trials: Insights From the ARTEMIS Trial (2017) (0)
Treatment of Acute Infarction With PCI Outcomes of Optimal or “ Stent-Like ” Balloon Angioplasty in Acute Myocardial Infarction : The CADILLAC Trial (2016) (0)
UNDERSTANDING READMISSIONS IN MEDICARE BENEFICIARIES DURING THE 90-DAY FOLLOW-UP PERIOD FOLLOWING AN AMI ADMISSION (2017) (0)
Abstract 3854: One-Year Cardiovascular Hospitalization Rates and Health Care Costs in Patients at Risk for Atherothrombosis: Results from the REACH Registry (2006) (0)
TCT-141 The Disutility of Nuisance Bleeding: Insights from the TRANSLATE ACS Registry (2013) (0)
ASSOCIATIONS BETWEEN DIFFERENT MODES OF DAPT CESSATION AND MAJOR ADVERSE EVENTS AT 6 MONTHS AND BEYOND: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Post-discharge Bleeding and Thienopyridine Discontinuation among AMI Patients Treated with PCI: Insights from the TRANSLATE-ACS Study (2011) (0)
TCT CONNECT-354 Prognostic Importance of Functional Status Versus Health Status in Patients With Heart Failure and Severe Secondary Mitral Regurgitation (2020) (0)
Abstract 2988: Changes in Coronary Revascularization Treatment Patterns Among Diabetic Patients: Results from the U.S. Medicare Program (2007) (0)
TRIPLE THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: A COMPARISON OF CLOPIDOGREL VERSUS PRASUGREL FROM THE TRANSLATE-ACS STUDY (2014) (0)
UNTREATED AORTIC STENOSISMORTALITY BY DIAGNOSIS SEVERITY: RESULTS FROM A LARGE REAL-WORLD DATABASE (2023) (0)
Reply: To PMID 22818074. (2013) (0)
Sex-Related Differences in Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe AorticStenosis (0)
Interventional cardiology: abstractClinical and economic outcomes of percutaneous coronary interventions in the elderly: An analysis of medicare claims data☆ (2004) (0)
JAMA Cardiology List of Peer Reviewers. (2017) (0)
TCT-66 Effects of dual antiplatelet therapy cessation among patients with diabetes mellitus after PCI with DES. (2016) (0)
TCT CONNECT-128 Impact of Time-of-Day of Surgical or Transcatheter Aortic Valve Replacement Procedure on Outcomes: A Propensity-score Matched Analysis From PARTNER Trials (2020) (0)
1121-62 Pattern of bracytherapy failure in unselected patients treated with gamma and beta radiation for saphenous vein graft in-stent restenosis (2004) (0)
Cost-Effectiveness of Percutaneous Coronary Interventions (2003) (0)
IN-HOSPITAL OUTCOMES OF CAROTID ARTERY STENTING IN PATIENTS WITH A CONTRALATERAL CAROTID OCCLUSION: ANALYSIS FROM THE CAROTID ARTERY REVASCULARIZATION AND ENDARTERECTOMY (CARE) REGISTRY (2011) (0)
Abstract 15708: Does Targeted Low Dose Heparin Negate the Efficacy and Safety of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention? Insights from a Propensity Score Matched Analysis of the EVENT Registry (2010) (0)
ealth-Related Quality of Life Following arotid Stenting Versus Endarterectomy (0)
TCT-501 Dual Antiplatelet Therapy Interruption For Surgery: Insights From The PARIS (Patterns Of Non-adherence To Anti-Platelet Regiments In Stented Patients) Registry (2014) (0)
PREDICTORS OF DUAL ANTIPLATELET THERAPY NON-ADHERENCE AFTER PCI: ONE-YEAR INSIGHTS FROM THE PARIS REGISTRY (2013) (0)
TICAGRELOR MONOTHERAPY AFTER PCI ACROSS THE SPECTRUM OF HIGH-RISK PATIENTS: A DEEP DIVE INTO THE TWILIGHT TRIAL (2022) (0)
Abstract 11: Impact of DES Versus BMS on Quality of Life Following Percutaneous Coronary Intervention: Insights From the TRIUMPH Registry (2011) (0)
REDUCING THE COST OF TAVR: AN EVALUATION OF THE IMPACT OF PERMANENT PACEMAKER RATE ON THE COST OF TRANSCATHETER AORTIC VALVE REPLACEMENT FROM THE HOSPITAL PERSPECTIVE (2014) (0)
The Challenges of Success: Maintaining Access to High Quality PCI in the Face of Declining Procedural Volumes (2014) (0)
TCT-205 Incidence and clinical outcomes associated with DAPT discontinuation in complex PCI patients: From the PARIS registry. (2016) (0)
Insights From the COURAGE Economic Study (2008) (0)
Abstract 36: Nuisance Bleeding after Percutaneous Coronary Intervention (2012) (0)
TCT-891 Outcomes Of Transcatheter Aortic Valve Replacement Versus Standard Therapy Among Women Deemed Too High Risk For Surgery In The PARTNER Trial (2012) (0)
EARLY CESSATION OF ADP RECEPTOR INHIBITORS AMONG ACUTE MYOCARDIAL INFARCTION PATIENTS TREATED WITH PCI: INSIGHTS FROM THE TRANSLATE-ACS STUDY (2013) (0)
Drug-eluting stents for stent thrombosis elevation acute myocardial infarction: do we need randomized trials? (2006) (0)
Abstract P328: Complete vs. ‘Culprit’ Only Revascularization in STEMI Patients With Multivessel Coronary Artery Disease: Practice Patterns, Predictors of Complete Revascularization and Impact on Health Status Outcomes (2011) (0)
Abstract 16453: Drug-Eluting Stent Event Registry of Thrombosis (DESERT): The International Drug-Eluting Stent Thrombosis Registry (2012) (0)
FEATURED ABSTRACT Correlation of treadmill test outomes with symptom improvement after treatment for aortoiliac claudication (2013) (0)
TCT-225 Impact of Age on the Disruption of Dual Antiplatelet Therapy: Analysis from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented) Patients Registry (2015) (0)
Mortality Risk of Postprocedural reatine Kinase-MB Elevation Following uccessful Versus Unsuccessful Stent Procedures (2016) (0)
Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients With Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization (0)
Abstract P232: Influence of Individualized Risk Prediction and Patient Preferences on Selection of Prasugrel Versus Clopidogrel at the Time of Percutaneous Coronary Intervention for an Acute Coronary Syndrome (2011) (0)
Analysis of Early Out-of Hospital Mortality after Transcatheter Aortic Valve Implantation among Patients with Aortic Stenosis Successfully Discharged from the Hospital and Alive at 30 days (From the PARTNER Trial) (2015) (0)
SYSTEMIC BUT NOT LOCAL BLEEDING IS ASSOCIATED WITH LONG-TERM MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (2011) (0)
Abstract 1061: Variation in the Number of Hospital Acquired Conditions at Heart Hospitals Among Medicare Beneficiaries in Fiscal Year 2007 (2009) (0)
CLOPIDOGREL WITH AND WITHOUT PROTON PUMP INHIBITOR USE: A PARIS REGISTRY ANALYSIS (2014) (0)
IMPACT OF PROTON PUMP INHIBITOR USE ON THE COMPARATIVE SAFETY AND EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL: INSIGHTS FROM TRANSLATE-ACS (2015) (0)
OralBleeding and the Hazards of AnticoagulationTCT-89 Tradeoff between Myocardial Infarction and Bleeding in Relation to Bleeding Risk: insights from PARIS registry (2017) (0)
IMPACT OF BASELINE LEFT VENTRICULAR FUNCTION AND AORTIC VALVE GRADIENT ON OUTCOMES IN PATIENTS TREATED WITH TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS FROM THE TVT REGISTRY (2015) (0)
Severity of and Recovery From Anemia After Transcatheter Aortic Valve Replacement: An Analysis of the Placement of Aortic Transcatheter Valves Trial and Registries (2022) (0)
TCT-654 Risk of Readmission for Acute Heart Failure, Subsequent Readmission, and Mortality Following Transcatheter Aortic Valve Replacement: An Analysis from PARTNER 1. (2016) (0)
Abstract 8888: Statin Therapy In Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions Is Associated with Better One Year Outcomes. An Analysis from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry (2011) (0)
IS MULTIVESSEL PRIMARY PCI ADVISABLE? DIFFERENCES IN CLINICAL OUTCOMES AMONG MEDICARE BENEFICIARIES WITHOUT CARDIOGENIC SHOCK UNDERGOING SINGLE VERSUS MULTI-VESSEL PCI DURING A PRIMARY ST-SEGMENT ELEVATED MYOCARDIAL INFARCTION HOSPITALIZATION IN FISCAL YEAR 2011 (2014) (0)
Patients. Evaluation and Outcomes Development of Systems of Care for ST-Elevation Myocardial Infarction (2007) (0)
Abstract 14469: Optimal Use of Drug-Eluting Stents in PCI: Implications of Healthcare Policy in Real-World Practice (2011) (0)
TCT-714 Association of Statin and Mortality after Transcatheter Aortic Valve Replacement (2018) (0)
Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". (2020) (0)
REAL-WORLD COST-EFFECTIVENESS OF THE MITRACLIP FOR THE TREATMENT OF HIGH RISK MITRAL REGURGITATION (2014) (0)
Correspondence to European Heart Journal - Quality of Care and Clinical Outcomes in response to letter by Dalal H. et al. (2021) (0)
Abstract 27: Anti-Anginal Medication Titration Among Patients With Residual Angina 6-Months After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From OPEN CTO Registry (2018) (0)
Original article Cost-effectiveness of prasugrel in a US managed care population (2012) (0)
FREQUENCY AND IMPACT OF SINGLE VERSUS DUAL ANTIPLATELET CESSATION ON ADVERSE CARDIAC EVENTS: RESULTS FROM THE PARIS REGISTRY (2013) (0)
Incidence, Predictors, and PrognosticImpact of Late Bleeding Complications After Transcatheter Aortic Valve Replacement (0)
Abstract 221: Transcatheter Aortic Valve Replacement is Associated with a Reduction in Hospitalization Rates: Insights from Nationwide Readmission Database (2019) (0)
CLINICAL OUTCOMES FOLLOWING GLYCOPROTEIN 2B/3A INHIBITION IN PCI FOR ACUTE CORONARY SYNDROME: INSIGHTS FROM THE NCDR® (2013) (0)
Abstract 18402: Impact of the Use of Different Bleeding Scales on the Rate of 6-Month Bleeding After PCI: Results from the PARIS Registry (2012) (0)
PCV34 COST-EFFECTIVENESS OF FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA: A DECISION ANALYSIS (2003) (0)
1043-43 The incremental hospital cost of treating major complications among medicare beneficiaries undergoing percutaneous coronary interventions (2004) (0)
1156-62 Economic outcomes of carotid stenting versus endarterectomy for high risk patients: Preliminary results from the SAPPHIRE trial (2004) (0)
Abstract 15728: Combining Risk-Adjusted Complications and Mortalities Avoided as a Single Measure of Ranking Hospital Performance Among Hospitals Performing Both PCI and CABG Procedures on Medicare Beneficiaries During Fiscal Year 2008: Is Performance Consistent Across Modalities? (2010) (0)
Quality of Life After PCI vs CABGAmong Patients With Diabetes andMultivessel Coronary Artery Disease A Randomized Clinical Trial (2013) (0)
Optimal Antiplatelet Therapy After PCI in High-Bleeding-Risk Patients (2021) (0)
IMPROVED OUTCOMES WITH DRUG ELUTING VERSUS BARE METAL STENTS IN SAPHENOUS VEIN GRAFT INTERVENTION: A REPORT FROM THE EVALUATION OF DRUG-ELUTING STENTS AND ISCHEMIC EVENTS (EVENT) REGISTRY (2011) (0)
Abstract 16705: Lower Education Level is Associated with Non-Adherence to Dual Antiplatelet Therapy After PCI: 6-Month Results from PARIS (2012) (0)
Abstract 13: Patient-reported Health Status Changes are Associated With Subsequent Clinical Outcomes After Transcatheter Valve Therapies: Insights From the Sts/tvt Registry (2020) (0)
THE INCREMENTAL HOSPITAL COST OF TREATING MAJOR COMPLICATIONS AMONG MEDICARE BENEFICIARIES UNDERGOING CORONARY ARTERY BYPASS GRAFT SURGERY (2013) (0)
TCT-158 Durability of Hemodynamic Results of Valve in Valve TAVR with Bioprosthetic Valve Fracture (BVF) (2017) (0)
Optimized dose matching for intravascular radiation using combined gamma and beta sources (2002) (0)
Long-Term Claudication Comparative Effectiveness Strategies of Care: Final 18 Month Outcomes from the CLEVER Study (2013) (0)
Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention (2019) (0)
Patient-Reported Versus Physician-Estimated Symptoms Before and After TAVR. (2021) (0)
Abstract P9: Comparing Hospital Ranking for Nonemergent PCI and CABG: How Many Hospitals Can Perform Both Procedures Above Average and Does It Matter? (2011) (0)
Abstract 16762: Lower Bleeding Risk Following PCI in Patients With Diabetes Prescribed Prolonged Dual Anti Platelet Therapy (2014) (0)
Abstract 334: Potential Risk Factors for Recurrent Coronary Revascularization and Hospitalization for Unstable Angina Following Acute Myocardial Infarction (2014) (0)
Impact of Pacemaker Implantation on 12-Month Resource Utilization Following TAVR Hospitalization (2019) (0)
TCT-124 Impact of level of anaesthesia using the Vancouver Clinical Pathway for transcatheter aortic valve replacement: Insights from the 3M TAVR Study (2018) (0)
ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND MACE DUE TO STOPPING ONE OR BOTH DRUGS: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Abstract 11541: Does Public Reporting Improve State Average Risk-Adjusted Outcomes Among Medicare Beneficiaries Undergoing Coronary Revascularization Procedures During Fiscal Year 2011 (2013) (0)
Incidence, Predictors, and Outcomes of Patients Discharged Home Versus Other Medical Facility After Transcatheter or Surgical Aortic Valve Replacement (2021) (0)
Abstract 1780: Use of Arteriotomy Closure Devices and the Risk of Vascular Complications: An Analysis of 227,879 Patients in the ACC-NCDR (2007) (0)
Clinical Tria Randomized Trial to Evaluate the elative Protection Against Post-Percutaneous oronary Intervention Microvascular ysfunction , Ischemia , and Inflammation mong Antiplatelet and Antithrombotic Agents he PROTECT – TIMI-30 Trial (2006) (0)
Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model (2020) (0)
PATTERNS OF ANGINA AND ANTIANGINAL MEDICATION USE AMONG PATIENTS FOLLOWING MI TREATED WITH PCI: INSIGHTS FROM TRANSLATE-ACS (2017) (0)
Effects of N-acetylcysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus (2009) (0)
TCT-18 Feasibility, safety and outcomes of chronic total occlusion revascularization in end-stage renal disease (2017) (0)
ASSOCIATION BETWEEN LEFT VENTRICULAR EJECTION FRACTION IMPROVEMENT AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT AND 5-YEAR SURVIVAL: AN ANALYSIS OF THE PARTNER TRIALS AND REGISTRIES (2021) (0)
IMPACT OF COMPLICATION COST ASSUMPTIONS ON THE REAL-WORLD COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN THE UNITED STATES (2015) (0)
Events) Registry Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents: A In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention (2011) (0)
Abstract 311: Statewide Hospital Performance on Total Lives Saved during Coronary Revascularization Procedures among Medicare Beneficiaries in Fiscal Year 2010 (2012) (0)
Reply: To PMID 23122802. (2013) (0)
Patient Recovery following Transcarotid or Transthoracic Transcatheter Aortic Valve Replacement (2021) (0)
1097-94 Early versus delayed intervention in non-ST-elevation acute coronary syndromes: A natural experiment from the CRUSADE initiative (2004) (0)
Expression Following Delivery to Porcine Myocardium (2002) (0)
Quality-of-Life Assessment in the EXCEL Trial. (2018) (0)
THE EFFECT AND RELATIONSHIP OF AGE AND FRAILTY ON SURVIVAL IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT (2018) (0)
Abstract 5615: A Comparison of Early Invasive Versus Conservative Therapy for Non-ST Elevation Myocardial Infarction Patients Excluded from Clinical Trials (2008) (0)
Trial Economic Impact of Angina After an Acute Coronary Syndrome : Insights (2009) (0)
STROKE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CAROTID DISEASE UNDERGOING TAVR: INSIGHTS FROM THE STS/TVT REGISTRY (2017) (0)
Abstract 225: Clinical Impact of Coronary Revascularization and Hospitalization for Unstable Angina in Acute Myocardial Infarction Patients (2014) (0)
Cranial Nerve Injury (CNI) in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): Incidence, Outcomes and Quality of Life (2014) (0)
Contemporary use of platelet function and pharmacogenomic testing among acute myocardial infarction patients treated with PCI in the United States: insights from the TRANSLATE-ACS study (2013) (0)
TEMPORAL ASSOCIATIONS BETWEEN TIME AFTER PERCUTANEOUS CORONARY INTERVENTION, DUAL ANTIPLATELET THERAPY CESSATION AND STENT THROMBOSIS IN THE CONTEMPORARY PCI ERA: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Abstract P350: Predicting the Restenosis Benefit of Drug-Eluting vs. Bare Metal Stenting Prior to Angiography: A Tool for Patients and Clinicians (2011) (0)
Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial (2003) (0)
TAVR WITH AND WITHOUT PACEMAKER IMPLANTATION DURING THE INDEX ADMISSION: IS THERE A DIFFERENCE IN 12-MONTH RESOURCE UTILIZATION AND OUTCOMES? (2018) (0)
Abstract WP349: Feeding Status After Stroke and Effect of Glyceryl Trinitrate: Data From the Efficacy of Nitric Oxide in Stroke (ENOS) Trial (2016) (0)
ECONOMIC IMPLICATIONS OF THE USE OF DIRECT THROMBIN INHIBITORS IN PERCUTANEOUS CORONARY INTERVENTION (2005) (0)
PCI-RELATED BLEEDING RISK BY ACCESS AND NON-ACCESS SITE IN THE NATIONAL CARDIOVASCULAR DATA REGISTRY® (2010) (0)
Abstract 39: Does Higher Use Of Non-invasive Testing Improve the Diagnostic Yield Of Coronary Angiography? (2013) (0)
P6030Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry (2018) (0)
Patterns of dual anti platelet therapy cessation in left main and proximal left anterior descending artery PCI: Results from the PARIS registry (2015) (0)
TCT-34 Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial. (2016) (0)
Abstract 6240: Cost Effectiveness of Radiofrequency Catheter Ablation vs. Anti-Arrhythmic Drugs for Paroxysmal Atrial Fibrillation (2008) (0)
TCT CONNECT-326 Impact of Diabetes Mellitus in Patients Undergoing Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial (2020) (0)
TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry. (2016) (0)
IMPACT OF BODY MASS INDEX ON MAJOR BLEEDING AFTER PCI: ONE-YEAR RESULTS FROM THE MULTICENTER PROSPECTIVE PARIS REGISTRY (2013) (0)
Abstract P14: Increased Prescription of Dual Antiplatelet Therapy Following CHARISMA and ACTIVE-W (2011) (0)
TRENDS IN RENAL COMPLICATION RATES AMONG MEDICARE BENEFICIARIES UNDERGOING PCI: FISCAL YEARS 2006 THROUGH 2008 (2011) (0)
TCT CONNECT-64 Impact of DAPT Cessation in High Bleeding-Risk Patients Undergoing PCI: Insights From the PARIS Registry (2020) (0)
Multivessel palmaz-schatz stenting: Acute results and long-term outcome (1996) (0)
AS-36: Independent U.S. Validation of the British Columbia Percutaneous Coronary Intervention Risk Score (2010) (0)
on a National Heart, Lung and Blood Institute Working Group Guided Antithrombotic Therapy: Current Status and Future Research Direction: Report (2014) (0)
TCT-77 Association of Residual Mitral Regurgitation after Transcatheter Aortic Valve Replacement with Readmission for Acute Heart Failure: An Analysis from PARTNER 1. (2016) (0)
IMPACT OF AGE ON THE MODES OF DUAL ANTIPLATELET THERAPY CESSATION: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY (2015) (0)
TCT-206 Tailoring the Intensity of Antiplatelet Pharmacotherapy to Ischemic and Bleeding Risk: A Cost Optimizing Simulation From PARIS. (2016) (0)
“De-Escalation” of Dual Antiplatelet Therapy for Patients Undergoing PCI for Acute MI (2021) (0)
Carotid stenting versus carotid endarterectomy: how relevant are quality of life and individual adverse events? (2012) (0)
Abstract 10118: Trends in Renal Complication Rates Among Medicare Beneficiaries Undergoing Percutaneous Coronary Interventions: Fiscal Years 2006 through 2009 (2011) (0)
Abstract 15618: PCI Outcomes among Medicare Beneficiaries during Fiscal Year 2010 at Hospitals with and without Cardiac Surgery On-Site (2012) (0)
Abstract 14117: Method of Assessing Medication Persistence and Clinical Outcomes: A Comparison of Patient Report and Pharmacy Fill Data From the ARTEMIS Trial (2018) (0)
APPROPRIATE USE CRITERIA AND HEALTH STATUS OUTCOMES AFTER CTO PCI: RESULTS FROM THE OPEN CTO REGISTRY (2017) (0)
Health Status after Transcatheter Mitral Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: COAPT Trial (2019) (0)
Abstract 9764: Clinical Characteristics and Temporal Trends Among Patients Presenting Late (>12 Hours After Symptom Onset) With ST-Elevation Myocardial Infarction - A Report From the NCDR® (2014) (0)
TCT-181 Early Changes in Quality of Life after Transcatheter Aortic Valve Replacement: Results from the 3M-TAVR Trial (2018) (0)
TCT-323 Length of Stay Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Association With 30-Day Readmissions and Implications for Healthcare Costs (2017) (0)
PREDICTORS OF CLINICAL SUPER-RESPONDERS IN THE COAPT TRIAL (2020) (0)
Abstract 12: Determinants of Health-Related Quality of Life after Percutaneous Coronary Intervention or Bypass Surgery: Insights from the SYNTAX Trial (2011) (0)
O-013 early ischemic core volion volumes predict infarct size in swift prime (2015) (0)
Abstract P20: One-Year Hospitalization Costs Associated with Carotid Stenting Versus Endarterectomy: Results from the CREST Trial (2011) (0)
4071Early changes in quality of life after transcatheter aortic valve replacement: One-year results from the 3M TAVR Study (2019) (0)
TICAGRELOR MONOTHERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN HIGH-RISK PATIENTS WITH OR WITHOUT HISTORY OF MYOCARDIAL INFARCTION. A PRESPECIFIED TWILIGHT SUBSTUDY (2021) (0)
Abstract 19520: Trends in Renal Complication Rates Among Medicare Beneficiaries Undergoing PCI: Fiscal Years 2009 Through 2013 (2015) (0)
Myocardial Infarction Incidence and Predictors of Myocardial Infarction Among Patients With Atrial Fibrillation (2016) (0)
Abstract 182: Radiofrequency Ablation for Atrial Fibrillation: Trends in Patients, Clinical Outcomes, and Resources Among Medicare Beneficiaries from Fiscal Year 2010 to Fiscal Year 2013. (2015) (0)
IMPACT OF FRAILTY ON CLINICAL OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING VERSUS PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM SYNTAX (2023) (0)
PCV126 REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA (2009) (0)
An optimal acute result after directional atherectomy or stent placement reduces the risk of subsequent restenosis. (1994) (0)
WHAT IS THE OPTIMAL RATE OF DRUG-ELUTING STENT USE? INSIGHTS FROM TEMPORAL ANALYSIS OF THE MULTICENTER EVENT REGISTRY (2010) (0)
Response to letters regarding article, "comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the assessing angiography (A2) project". (2013) (0)
Impact of Transcatheter Aortic Valve Replacement on Hospitalization Rates: Insights From Nationwide Readmission Database (2021) (0)
MEDICARE REIMBURSEMENT ASSOCIATED WITH AN AMI HOSPITALIZATION AND 90-DAYS POST-DISCHARGE (2017) (0)
B-45 | Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Story (2022) (0)
Abstract 1: Impact of Predicted Bleeding Risk on the Cost-Effectiveness of Direct Thrombin Inhibition vs. Heparin Monotherapy for Patients Undergoing PCI (2011) (0)
Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure (2021) (0)
INTERVENTIONAL CARDIOLOGY FELLOWS AND PROCEDURAL COMPLICATIONS AFTER PERCUTANEOUS CORONARY INTERVENTION (2011) (0)
Abstract 69: Defining Futility in Transcatheter Aortic Valve Replacement (2013) (0)
THE ASSOCIATION OF P2Y12 INHIBITOR COPAYMENT REDUCTION WITH OUTCOMES AT HOSPITALS WITH AND WITHOUT MEDICATION ASSISTANCE PROGRAMS (2019) (0)
A Hybrid Comparison Of Cost-Effectiveness Of Transcatheter Aortic Valve Replacement Between Randomized Clinical Trials And Real World Practice In Treating Patients With Severe Aortic Stenosis (2014) (0)
TCT-749 The Influence of Severe Aortic Valve Stenosis on 5-Year Economic Outcomes Among Older Medicare Beneficiaries (2019) (0)
USING PRESENT ON ADMISSION CODES TO REPORT TRENDS IN RENAL COMPLICATION RATES AMONG MEDICARE BENEFICIARIES UNDERGOING PCI: FISCAL YEARS 2009 AND 2010 (2012) (0)
In-Vivo Assessment of Balloon Expansion and Stent Recoil in Normal Porcine Coronary Arteries: On-line Measurement Using an Imaging Guidewire (1998) (0)
Abstract 106: Concomitant Contrast Dependent Procedures are Predictors of Increasing PCI Assoicated Renal Complications among Medicare Beneficiaries (2013) (0)
, Versus Stenting Trial ( CREST ) Standard Surgical Risk : Results From the Carotid Revascularization Endarterectomy Costs and Cost-Effectiveness of Carotid Stenting Versus Endarterectomy for Patients at (2012) (0)
Abstract 341: Cost of Care Implications for Unstable Angina and Coronary Revascularization Readmissions Following Acute Myocardial Infarction (2015) (0)
Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents : Primary Endpoint Results from the Dual Antiplatelet Therapy Study (2014) (0)
Will drug-eluting stents bankrupt the healthcare system? (2006) (0)
Will drug-eluting stents bankrupt the healthcare system? Are Drug-Eluting Stents Cost-Effective? It Depends on Whom You Ask C ONTROVERSIES IN C ARDIOVASCULAR M EDICINE (2006) (0)
PREDICTORS OF MORTALITY AMONG MEDICARE BENEFICIARIES UNDERGOING PCI WITH STEMI OR NSTEMI (2016) (0)
Abstract 15: Temporal Trends of Drug Eluting Stent Use After Myocardial Infarction: Does More Selective Utilization Impact Health Status Outcomes? (2011) (0)
Economic considerations of drug-eluting stents (2005) (0)
Rehospitalization Events After Aortic Valve Replacement: Insights From the PARTNER Trial (2022) (0)
PROGNOSTIC IMPLICATIONS OF DISCHARGE PATTERNS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (2019) (0)
Versus Blood Pressure Level Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa : Absolute Risk (2005) (0)
Abstract 6230: Willingness-to-Pay to Avoid Restenosis Following Percutaneous Coronary Intervention in Canadian Patients; A Contingent Valuation (2008) (0)
Abstract 20166: Development of a Risk Prediction Model for 1-Year Mortality After Surgical vs. Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis (2016) (0)
Abstract 17178: Variability in Pacemaker Implantation in the 3M TAVR Study: Indications, Outcomes and Implications (2019) (0)
DUAL ANTIPLATELET THERAPY (DAPT) CESSATION AND CARDIOVASCULAR RISK IN RELATION TO AGE: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY (2019) (0)
Impact of Clopidogrel Pretreatment on Ischemic Complications of PCI among Bivalirudin-Treated Patients: Results from the EVENT Registry (2010) (0)
ACUTE MYOCARDIAL INFARCTION WITH CARDIOGENIC SHOCK AMONG MEDICARE BENEFICIARIES: DO REPERFUSION AND REVASCULARIZATION MATTER? (2015) (0)
Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease after (2017) (0)
Effect ofMedication Copayment Vouchers on P 2 Y 12 Inhibitor Use andMajor Adverse Cardiovascular Events Among Patients WithMyocardial Infarction The ARTEMIS Randomized Clinical Trial (2018) (0)
Abstract 84: Impact of Education on Dual Antiplatelet Therapy Adherence (2012) (0)
Abstract 8974: Standard and off-Label Use of Drug-Eluting Stents and Patient-Reported Angina Three Years After Percutaneous Coronary Intervention - A Report From the NHLBI-sponsored Dynamic Registry (2010) (0)
862-3 Subacute stent thrombosis after successful placement of sirolimus-eluting coronary stents: Real-world experience (2004) (0)
a ents Overes mate the oten al Bene ts of Elec ve ercutaneous Coronary Interven on (2018) (0)
Abstract 379: Trends in Coronary Revascularization Procedures among Medicare Beneficiaries between Fiscal Years 2010 and 2013 (2015) (0)
TCT-665 Association of Paravalvular Leak after Transcatheter Aortic Valve Replacement with Readmission for Acute Heart Failure: An Analysis from PARTNER 1. (2016) (0)
Abstract 12647: Race and Gender Differences in Post-Myocardial Infarction Angina Frequency and Rehospitalization Risk (2015) (0)
THE IMPACT OF SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON TRANSCATHETER AORTIC VALVE REPLACEMENT: FROM THE SAPIEN 3 REGISTRY (2019) (0)
Abstract 12615: Angina Frequency and Unplanned Readmissions after Multivessel vs. Culprit Vessel Only Percutaneous Coronary Intervention Strategy Among Patients Presenting With Acute Myocardial Infarction- 6 Week Outcomes From the TRANSLATE-ACS Observational Study (2014) (0)
Abstract 267: Cost-Effectiveness of Transradial PCI: A Decision-Analytic Model (2012) (0)
Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement Results From the PREMIER Registry Coronary Heart Disease (2006) (0)
The Descending Thoracic Aorta: Forgotten Vascular Access for Endovascular Device Delivery (2016) (0)
Abstract 13139: Decline in Clopidogrel Discontinuation Rates and its Association with Mortality after Acute Myocardial Infarction (2010) (0)
PLATELET REACTIVITY, P2Y12 RECEPTOR INHIBITOR SELECTION AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY (2015) (0)
Abstract P4: Does the Expected Reduction in Restenosis from Drug-Eluting Stents Predict Actual Use? An Assessment of Treatment-Risk Paradox Using the C-Statistic (2011) (0)
IMPACT OF PERIPHERAL ARTERIAL DISEASE ON OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR IN HEART FAILURE: FROM THE COAPT TRIAL (2022) (0)
Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension (2022) (0)
Abstract 11150: Trends in Coronary Revascularization Procedures among Medicare Beneficiaries Between Fiscal Years 2008 and 2011 (2013) (0)
TAVR USING TRANSCAROTID VASCULAR ACCESS: IN-HOSPITAL AND INTERMEDIATE TERM OUTCOMES (2017) (0)
Who is at risk to develop late drug-eluting stent thrombosis while on dual antiplatelet therapy? A subset analysis from the Drug Eluting Stent Event Registry of Thrombosis (DESERT) (2013) (0)
The challenges of success: maintaining access to high-quality percutaneous coronary intervention in the face of declining procedural volumes. (2014) (0)
TCT-490 Frequency And Impact Of Nuisance Bleeding On Adverse Events After Percutaneous Coronary Intervention: 2-Year Results From The Patterns Of Non-Adherence To Antiplatelet Regimens In Stented Patients (PARIS) Registry (2014) (0)
WHAT IS THE IMPACT OF COMPLICATIONS DURING THE INDEX HOSPITALIZATION ON RESOURCE UTILIZATION DURING THE 90-DAY FOLLOW-UP PERIOD ASSOCIATED WITH CABG SURGERY AMONG MEDICARE BENEFICIARIES? (2017) (0)
NEW-ONSET ATRIAL FIBRILLATION FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: INCIDENCE, ANTICOAGULANT STRATEGY, AND OUTCOMES (2017) (0)
Abstract 227: Treatment Variations in Early Dual Antiplatelet Therapy for Nstemi Patients Who Are at Risk for Undergoing Cabg (2015) (0)
P511Incidence and patterns of dual antiplatelet therapy cessation among patients with peripheral arterial disease after percutaneous coronary intervention: insights the PARIS registry (2017) (0)
When Is Better Not Good Enough ? (2008) (0)
Incentivizing Multidisciplinary Care in Cardiovascular Medicine (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Joel Cohen?

David Joel Cohen is affiliated with the following schools:

David Joel Cohen's Academic­Influence.com Rankings

David Joel Cohen's Degrees

Similar Degrees You Can Earn

Why Is David Joel Cohen Influential?

David Joel Cohen's Published Works

Published Works

What Schools Are Affiliated With David Joel Cohen?

David Joel Cohen's AcademicInfluence.com Rankings